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This Month in the Journal
X-Linked Dilated Cardiomyopathies, by D’Adamo etGene therapy is the topic of this month’s ‘‘Human Ge-
al. (p. 862); and INVM Is Allelic with Barthnetics ’97’’ series. Hall et al. (p. 785) discuss one of the
Syndrome, by Bleyl et al. (p. 868)major challenges in cancer gene therapy, the need to
suppress the growth of even those tumor cells that fail Taffazins are recently discovered proteins with no
to take up or express a transgene. Kozarsky and Couture known biochemical function that are highly conserved
(p. 790) describe a variety of therapeutic strategies that between humans, nematodes, and yeast. In humans,
affect mRNAs directly, rather than targeting DNA se- these proteins arise from alternatively spliced mRNAs,
quences. In ‘‘Insights from Model Systems,’’ Hendrick- the products of a single X-linked gene, G4.5. One or
son reviews DNA double-strand-break repair pathways. more of the taffazins are altered in Barth syndrome
Many of the molecules involved are conserved between (BTHS), a cardiomyopathy that also presents with
mammalian and yeast cells and have been implicated in growth arrest, neutropenia, and defects in skeletal mus-
hereditary cancer or immunodeﬁciency disorders. cle. Now, two groups have implicated G4.5 in other
X-linked infantile cardiomyopathies. D’Adamo et al. re-
port that mutations in G4.5, including missense muta-Renal Cysts in Tuberous Sclerosis, by Sampson et al.
tions in alternatively spliced exons, may lead to endocar-(p. 843)
dial ﬁbroelastosis or to severe X-linked cardiomyopathy,The TSC2 gene underlies many cases of tuberous sclero-
diseases that had been considered distinct from BTHS.sis, which presents with hamartomas, often on the skin
D’Adamo et al. suggest that the clinical differences be-or in nervous tissue. Renal symptoms include angiomyo-
tween BTHS and the other condition occur because thelipomas and, in some patients, kidney cysts. Here, Samp-
mutations affect different subsets of the taffazins. How-son and colleagues describe genomic deletions in people
ever, Bleyl et al. report on a Utah kindred with a muta-with both tuberous sclerosis and kidney cysts. They
tion identical to one of the point mutations found byshow that, in 18 of 27 unrelated subjects, constitutive
D’Adamo et al., and in this family the noncardiac symp-deletions in TSC2 also affected the tightly linked PKD1
toms of BTHS present inconsistently. Hence, not all thegene, a major gene involved in autosomal dominant
clinical heterogeneity in these conditions can be ascribedpolycystic kidney disease. Thus, tuberous sclerosis with
to different mutations in G4.5.kidney cysts appears to be a contiguous gene–deletion
syndrome. Consistent with this model, Sampson et al.
Familial Glaucoma Iridogoniodysplasia Maps to 6p25,ﬁnd that an individual who carries a deletion in PKD1
by Jordan et al. (p. 882)that leaves the coding region intact shows only mild
Juvenile-onset glaucoma and a distinctive slate-gray–cystic disease, and they ﬁnd that somatic mosaicism for
colored iris are diagnostic criteria for familial glaucomadeletions in the two genes leads to cystic disease with
iridogoniodysplasia (FGI), an autosomal dominant eyevariable severity.
disorder. This condition has been studied in a large nine-
generation Scots family in which the earliest record of
Fructose-1,6-Bisphosphatase Deﬁciency, by Kikawa et disease dates from the 18th century. Working with a
al. (p. 852) branch of this pedigree, Jordan and co-workers have
Fructose-1,6-bisphosphatase is a key regulator of gluco- mapped the FGI locus to a 6.4-cM region on 6p25. Their
neogenesis, and deﬁciency of this enzyme leads to life- data show that FGI is distinct from Rieger syndrome
threatening metabolic defects in infants. Kikawa et al. but suggest that it may be allelic with primary congenital
have identiﬁed three novel and one known disease allele glaucoma, a recessive disorder, or with iridogoniodys-
in the FBP1 gene in a set of 11 unrelated Japanese fami- genesis anomaly.
lies. Two of these mutations are missense alterations
at conserved sites in the protein sequence. The authors Linkage of ICCA Syndrome to Human Chromosome
suggest that these four mutations, which abolish enzy- 16, by Szepetowski et al. (p. 889)
matic activity when they are expressed in bacteria, act Szepetowski and co-workers have identiﬁed families in
by blocking the effects of AMP, an allosteric activator which two clinically distinct convulsive disorders segre-
of the enzyme. gate, apparently as a single autosomal dominant trait.
Benign infantile familial convulsions are observed in
most affected individuals in these families, within the
1st year of life. Paroxysmal choreoathetosis (CA), on
the other hand, is ﬁrst seen at age 6 years and may 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6104-0001$02.00 exhibit age-dependent penetrance. Szepetowski et al. ex-
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clude linkage of infantile convulsions and CA (ICCA) ber of FA loci to eight. To date, only two of these,
FAA and FAC, have been cloned, but characterizing thewith any of the reported epilepsy-susceptibility loci, but
they link ICCA with a novel locus on chromosome 16. remaining genes may provide new insights into chromo-
somal stability or DNA repair.The identiﬁcation of ICCA as a single genetic entity
strengthens the argument that CA should be regarded
Predictive Testing for Huntington Disease, byas a type of epilepsy.
Almqvist et al. (p. 945)
Evidence for Eight Fanconi Anemia Genes, by Joenje
Risk assessments that genetic counselors provide theiret al. (p. 940)
clients are always provisional. If more family data are
At the cellular level, Fanconi anemia (FA) is a chromo- collected, if diagnostic criteria change, or if genotyping
somal breakage disorder, and FA lymphoblasts are hy- errors are discovered, it may be necessary to contact
persensitive to DNA cross-linking agents. FA is geneti- clients and offer them a revised risk assessment. Alm-
cally heterogeneous, as shown by the patterns of qvist et al. have collected case studies of dramatic rever-
complementation in cell-fusion studies using cell lines sals in assessed risk for Huntington disease. They report
from FA individuals. The chromosomal instability phe- here that clients’ responses were complex and not readily
notype no doubt leads to the clinical features of FA, predictable, regardless of whether the newer assessment
such as loss of myeloid cells and susceptibility to leuke- is for greater or lesser risk than was originally stated.
mia, but the molecular basis of the condition is not
understood. Joenje and colleagues have deﬁned three JOHN ASHKENAS
Editorial Fellownovel complementation groups, bringing the total num-
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